Page 282 - 2021_02-Haematologica-web

596
Letters to the Editor
grants and personal fees from Ono, grants and personal fees from Mundipharma, grants and personal fees from MSD, grants and personal fees from Zenyaku, personal fees from Sumitomo, personal fees from Asahi Kasei, grants and personal fees from Bristol-Myers Squibb, grants and personal fees from Daiichi Sankyo, grants and personal fees from AstraZeneca, personal fees from Linical, personal fees from Pharma International, personal fees from Fujimoto, grants from Abbvie, grants from Astellas, grants from Amgen Astellas Biopharma, grants from Otsuka, grants from Novartis, grants from Pfizer, grants from Solasia, grants from Bayer, grants from Symbio, grants from CMIC, grants from Quintiles, grants from IQvia, outside the submitted work; KI reports grants and personal fees from Eisai, grants and personal fees from MSD, grants and personal fees from Takeda, grants and personal fees from Janssen, personal fees from Bristol Myers Squib, personal fees from Dainihon Sumitomo, grants and personal fees from Mundipharma, personal fees from Nihon Mediphysics, grants and personal fees from Chugai, grants and personal fees from Astra Zeneca, grants and personal fees from Abbvie, grants and personal fees from Bayer, grants and personal fees from Ono, grants from Gilead, grants from Zenyaku, grants and personal fees from Celgene, grants from Solasia, grants from Symbio, grants from Astellas, grants from Astellas Amgen, grants from Bayer and Daiichi Sankyo, personal fees from Kyowa Hakko Kirin, outside the submitted work; KT reports personal fees from Zenyaku Kogyo, grants and personal fees from Eisai, grants and personal fees from Takeda, grants and personal fees from Mundipharma, personal fees from HUYA Bioscience International, grants and personal fees from Kyowa Hakko Kirin, grants and personal fees from Celgene, grants and personal fees from Chugai Pharma, grants and personal fees from Ono Pharmaceutical, personal fees from Yakult , personal fees from Daiichi Sankyo, personal fees from Bristol-Myers Squibb, personal fees from Meiji Seika Kaisha, personal fees from Solasia Pharma, personal fees from Verastem , grants from Janssen, grants from Abbvie, outside the submitted work; YK reports grants, personal fees and other from Pfizer, personal fees from Astellas, personal fees from Symbio, outside the submitted work.
Contributions: ToS collected the data. ToS, SF, YI, SH, SY, SM, WM, TaS, DM, KI, KT, and YK provided the cases. AM and HT performed the immunohistological evaluations. ToS, JN, SY, and TU performed the genetic analyses and interpreted the data. ToS and SF wrote the preliminary draft of the manuscript. All authors revised the subsequent drafts and approved the final version for submission.
Acknowledgments: the authors would like to thank laboratory technicians MS, ST, MM and IM for performing FISH analysis and extra immunostaining for this study.
References
1. Vannata B, Conconi A, Winkler J, et al. Late relapse in patients with diffuse large B-cell lymphoma: impact of rituximab on their inci- dence and outcome. Br J Haematol. 2019;187(4):478-487.
2. Larouche JF, Berger F, Chassagne-Clement C, et al. Lymphoma recur- rence 5 years or later following diffuse large B-cell lymphoma: clini- cal characteristics and outcome. J Clin Oncol. 2010;28(12):2094-2100.
3. Stephens DM, Li H, LeBlanc ML, et al. Continued risk of relapse independent of treatment modality in limited-stage diffuse large B- Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736. J Clin Oncol. 2016;34(25):2997-3004.
4. Lenz G, Wright G, Dave SS et al. Stromal gene signatures in large-B- cell lymphomas. N Engl J Med. 2008;359(22):2313-2323.
5. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103(1):275-282.
6. Chapuy B, Stewart C, Dunford AJ et al. Molecular subtypes of dif- fuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679-690.
7. Schmitz R, Wright GW, Huang DW et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396- 1407.
8. Juskevicius D, Lorber T, Gsponer J et al. Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis. Leukemia. 2016;30(12):2385-2395.
9. Broseus J, Chen G, Hergalant S et al. Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses. Oncotarget. 2016;7(51):83987-84002.
10. Wang Y, Farooq U, Link BK et al. Late relapses in patients with dif- fuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2019;37(21):1819-1827
11. de Jong D, Glas AM, Boerrigter L et al. Very late relapse in diffuse large B-cell lymphoma represents clonally related disease and is marked by germinal center cell features. Blood. 2003;102(1):324-327.
12. Horton SJ, Giotopoulos G, Yun H et al. Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors. Nat Cell Biol. 2017;19(9):1093-1104.
13. Ying CY, Dominguez-Sola D, Fabi M et al. MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma. Nat Immunol. 2013;14(10):1084-1092.
14.Ortega-Molina A, Boss IW, Canela A et al. The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. Nat Med. 2015; 21(10):1199-1208.
haematologica | 2021; 106(2)